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BRCA1 Supports XIST RNA Concentration
on the Inactive X Chromosome
and ovarian cancer. Since tumors that arise in these
individuals reveal loss of heterozygosity at BRCA1 with
retention of the mutant allele, this gene is considered a
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BRCA1, a breast and ovarian tumor suppressor, colo- role of these interactions in BRCA1-dependent tumor
calizes with markers of the inactive X chromosome suppression is poorly understood.
(Xi) on Xi in female somatic cells and associates with The specific molecular mechanism underlying the
XIST RNA, as detected by chromatin immunoprecipi- gender and tissue specificity of the BRCA1 cancer syn-
tation. Breast and ovarian carcinoma cells lacking drome in humans, while potentially linked to the activi-
BRCA1 show evidence of defects in Xi chromatin ties noted above, remains unclear. The breast and ovary
structure. Reconstitution of BRCA1-deficient cells are both estrogen-responsive organs, and BRCA1 has
with wt BRCA1 led to the appearance of focal XIST been reported to interact with the estrogen receptor
RNA staining without altering XIST abundance. Inhib- (ER) and to influence both ligand-dependent and -inde-
iting BRCA1 synthesis in a suitable reporter line led pendent ER activation (Fan et al., 2001; Zheng et al.,
to increased expression of an otherwise silenced Xi- 2001). In addition, there may be a role for BRCA1 in
located GFP transgene. These observations suggest breast development (Xu et al., 1999). The extent to which
that loss of BRCA1 in female cells may lead to Xi per- these properties underlie its gender- and tissue-specific
turbation and destabilization of its silenced state. tumor suppression mechanism is unknown.
BRCA1 mRNA is highly expressed in the testis (Black-
Introduction shear et al., 1998). In analyzing mouse testis, we noted
that BRCA1 is heavily concentrated on the X chromo-
Women harboring a mutation in one allele of the BRCA1 some in pachytene spermatocytes. The X chromosome
gene have a significantly increased lifetime risk of breast in these cells is transcriptionally inactive, having under-
gone changes reminiscent of X chromosome inactiva-
tion in female somatic cells (Richler et al., 1992). This7 Correspondence: david_livingston@dfci.harvard.edu
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Figure 1. Association of BRCA1 and Markers of the Inactive X Chromosome
(A–C) Immunostaining for BRCA1 was performed on sections of mouse testis. Low-power view of testis stained for BRCA1 (FITC). The bright
autofluorescent structure is the boundary of a spermatic tubule. Regions of zygotene (Z) and pachytene (P) spermatocytes are marked. (B)
Close-up view of BRCA1 immunostaining of pachytene cells; DAPI nuclear staining is shown in blue; (C) pachytene cells coimmunostained
for BRCA1 (green) and macrohistone H2A1 (MH2A1, red). Areas of staining overlap are shown in yellow; DAPI nuclear staining in blue.
(D–L) Combined immunostaining of telomerase-immortalized human mammary epithelial cells (D–F) with a monoclonal antibody to BRCA1
(D) and a polyclonal antibody to MH2A1 (E). Merged image (F). (G)–(L) depict combined immunostaining of HMEC-t (G–I) and WI-38 cells (J–L)
for BRCA1 (G and J) and RNA FISH for XIST (H and K). Merged images (I and L).
(M) ChIP (see Experimental Procedures) was performed on 293 cells using purified antibodies to BRCA1, BARD1, and an irrelevant antibody.
RNA was extracted from each ChIP and subjected to RT-PCR using primers specific for a region in exon 6 of XIST. The plus and minus signify
PCR amplification with and without first round RT. The last two lanes are controls using cellular RNA as template.
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Table 1. Colocalization of BRCA1 with XIST and Macrohistone H2A1
Cell Type % XIST () % BRCA1 () % of BRCA1() Cells that Exhibit Colocalization of BRCA1 and XIST
HMEC-t 93 72 5.0
WI-38 95 54 10
IMR-90 96 48 8.5
Cell Type % MH2A1 () % BRCA1 () % of BRCA1() Cells that Exhibit Colocalization of BRCA1 and MH2A1
HMEC-t 23 78 3.7
WI-38 41 52 8.0
Ishikawa 11 67 12
In experiments performed on HMEC-t, (telomerase-immortalized primary human mammary epithelial cells), WI-38, Ishikawa, and IMR90 cells,
200–300 cells of each asynchronous culture were analyzed for BRCA1 and XIST, focal MH2A1 and XIST costaining, and focal BRCA1 and
MH2A1 costaining. In all instances, colocalization refers to costaining of a single, large, discrete nuclear body.
observation prompted the question of whether the not observed in all cells. Indeed, it varied from 4% to
12%, depending upon the cell line/strain analyzed (seeBRCA1 interacts with the inactive X chromosome in
female somatic cells. Table 1). In keeping with these findings, colocalization
was largely apparent in mid/late S phase cells (data not
shown).Results
Colocalization of BRCA1 with the Inactive X Coassociation of BRCA1 and BARD1
with XIST RNAChromosome in Spermatocytes
and Female Somatic Cells Chromatin immunoprecipitation (ChIP) analyses were
performed on 293 cells using affinity-purified polyclonalBRCA1 decorates the unpaired X chromosome in human
pachytene spermatocytes (Scully et al., 1997). To further BRCA1 antibodies. 293 cells are female, and the majority
contain three X chromosomes, two of which are inactiveevaluate this observation, we studied the localization of
BRCA1 in sections of mouse testis. In pachytene cells, (Gilbert et al., 2000). After ChIP, RNA was isolated and
subjected to RT/PCR for XIST. A positive signal for XISTit decorated a specific curvilinear structure that is mor-
phologically suggestive of the XY body. This was con- was observed in the anti-BRCA1 ChIP (Figure 1M). No
such signal was detected in ChIPs generated with unre-firmed by costaining of BRCA1 in these structures with
an antibody to macrohistone H2A1 (Figure 1C), a known lated antibodies or when PCR was performed in the
absence of a prior RT step (Figure 1M and data notXY body component (Richler et al., 2000). The XY body
contains the unpaired X chromosome that has become shown). Similar results were obtained with extracts of
WI-38 and with two monoclonal antibodies to BRCA1densely heterochromatic, silenced, and localized at the
nuclear periphery, much like the inactive X chromosome (SD118 and SG11, data not shown). ChIP, performed
with an antibody to BARD1, a structurally related protein(Xi) in female somatic cells (Handel and Hunt, 1992;
Huynh and Lee, 2001). Like Xi, the pachytene X is coated that efficiently heterodimerizes with BRCA1, also coim-
munoprecipitated XIST RNA (Figure 1M). By contrast,with the noncoding XIST RNA and accumulates macro-
histone H2A1 (MH2A1), and its histone H3 is methylated the same ChIPs lacked H19 RNA, another noncoding
RNA (Figure 1N). These findings suggest that BRCA1on lysine 9 (Ayoub et al., 1997; Costanzi and Pehrson,
1998; Richler et al., 2000; Cowell et al., 2002). and BARD interact, directly or indirectly, with XIST RNA.
Although an XIST cDNA signal was reproducibly ob-Analysis of multiple female human cell lines and
strains revealed that in a subset of unsynchronized cells, tained from the ChIP when primers specific for a seg-
ment of the internal portion of XIST exon 6 were utilized,BRCA1 immunostaining colocalized with MH2A1 on a
discrete nuclear structure (Figures 1D–1F). Concurrent no such signal was detected when primers that flank
the exon 1/2 junction or the exon 5/6 junction wereimmunostaining for BRCA1 and fluorescent in situ hy-
bridization (FISH) for XIST RNA revealed significant colo- used (Figure 1O), suggesting that BRCA1 and BARD1
associate with a specific segment(s) of XIST RNA.calization of these signals in a subset of both WI-38 and
telomerase-immortalized human mammary epithelial
cells (HMEC-t) (Figures 1G–1L). Colocalization of BRCA1 Absence of XIST Staining in Human and Murine
Tumor Cells that Lack Wild-Type BRCA1and MH2A1 and BRCA1 and XIST on a large nuclear
structure was detected in a subset of all lines/strains To determine whether BRCA1 interacts functionally with
Xi, we examined features of Xi in tumor cells that lacktested (see Figure 1 and Table 1). Since BRCA1 nuclear
staining occurs primarily in S phase and MH2A1 staining BRCA1. HCC1937 is a human breast cancer cell line
that carries a germline mutation (5382insC) in oneof Xi can only be detected during late G1 and S (Chad-
wick and Willard, 2002), BRCA1/MH2A1 costaining was BRCA1 allele and has lost the wt allele (Tomlinson et
(N) ChIPs, performed on 293 cell extract, were subjected to RT-PCR using primers specific for H19 RNA.
(O) ChIP was performed as in (M), except that the relevant PCR primers spanned a region covering the XIST exon 1/2 junction (left) or a region
spanning the Xist exon 5/6 junction (right).
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Figure 2. Absence of Focal XIST RNA and MH2A1 Staining in BRCA1/ Cells
(A) DNA FISH using an X chromosome-specific probe was performed on HCC1937 cells. 70% of the cells revealed two X foci. DAPI
counterstaining is shown in blue.
(B) RNA FISH for XIST was performed on IMR-90 female diploid fibroblasts (left) and on HCC1937 cells (right). The FISH signal is in red; the
DAPI nuclear staining is shown in blue. 96% of IMR-90 revealed focal XIST staining, while none of the HCC cells contained a focal XIST
signal.
(C) Simultaneous immunofluorescent (IF) staining for MH2A1 (left, green signal) and RNA FISH for XIST (middle, red signal; DAPI nuclear
BRCA1 Supports XIST Localization
397
Table 2. Correlation of BRCA1 Genotype and Focal XIST, MH2A1, and H3mK9 Localization in Breast and Ovarian Tumors
Tumor Type B1 Genotype BRCA1 IF XIST MH2A1 H3mK9
Human ovarian sporadic    ND
Human ovarian S713stop    ND
Human breast sporadic    
Human breast sporadic  ND ND 
Human breast sporadic  ND ND 
Human breast C61G    
Human breast 4476 ins G    
Human breast 3448 del A    a
Human breast 3600 del 11    
Murine breast wt ND   ND
Murine breast Del exon 11 ND   ND
Murine breast Del exon 11 ND   ND
The generic nature of each tumor, its BRCA1 genotype (where known), and its BRCA1, XIST, MH2A1, and (where noted) histone H3mK9
staining characteristics are recorded for a series of human and murine tumors. Tissues were scored () for XIST and MH2A1 staining if 5%
of malignant cells exhibited focal staining. IF for BRCA1 in murine breast tissue was not obtained (ND). All analyses were performed as
described in Experimental Procedures.
a Small patches of focal, H3mK9-staining cells were detected in this sample against a much larger backdrop of negative staining cells in
tumor-rich regions. The identities of the positive staining cells are not known.
al., 1998). These cells synthesize no wt BRCA1, although shown). Although limited in quantity, these results reveal
that the link between BRCA1 expression and XIST local-they do produce a mislocalized, truncated product
(Scully et al., 1999). Most HCC1937 cells carry two X ization occurs in both cultured and primary BRCA1-
deficient cells.chromosomes (Figure 2A), although HCC are aneuploid
and contain minor subpopulations of large cells bearing Similar findings were obtained with cell lines and fro-
zen sections derived from BRCA1/ murine breast car-6–8 X chromosomes (data not shown). Notably, nearly
all HCC1937 cells, despite their2 X chromosomal con- cinomas (Figures 2R and 2S; Table 2; Brodie et al., 2001).
By contrast, a cell line derived from a spontaneous mu-tent, lacked focal XIST staining (Figure 2B). Unlike dip-
loid female fibroblasts (IMR-90 or WI-38), they also rine mammary tumor and frozen sections of breast can-
cers from wt mice revealed BRCA1 nuclear immuno-lacked focal MH2A1 staining (Figure 2C). Loss of XIST
and MH2A1 staining is not just a consequence of aneu- staining, focal Xist staining by RNA FISH, and focal
macrohistoneH2A staining (Figures 2L–2O and Table 2).ploidy, since other aneuploid, female cancer cell lines
(e.g., 293 and OVCAR3) maintain focal XIST and MH2A1/
Xi staining (data not shown). Effect of Reconstituting HCC1937
with Wild-Type BRCA1To determine whether the loss of focal XIST and
MH2A1 staining is a consistent finding in BRCA1-defi- Stable reconstitution of HCC1937 cells with wt BRCA1
can be achieved by recombinant retroviral infectioncient tumor cells, frozen sections of multiple human
ovarian and breast cancers were analyzed. Sections (Scully et al., 1999). The ectopically expressed protein
is properly localized in nuclear foci and present at nearlyfrom cases of sporadic breast and ovarian cancer re-
vealed BRCA1 nuclear staining in a significant subset physiological levels (Scully et al., 1999). Unlike the situa-
tion in HCC1937 cells transduced with vector alone, inof tumor cells (Figures 2D and 2L and Table 2). Most
cells also displayed focal XIST and MH2A1 staining (Fig- which 1% of cells had detectable XIST staining, focal
XIST staining was present in65% of the BRCA1-recon-ures 2F and 2G). However, when the four breast and
one ovarian cancer arising in BRCA1/ women were stituted cells (Figures 3A and 3B). A few large cells con-
tained several XIST-staining foci. Most likely, these cellsanalyzed, none revealed focal XIST or MH2A1 staining
(compare Figures 2F and 2G with 2J and 2K, see also carry multiple X chromosomes (data not shown).
Similar results were obtained during the analysis ofTable 2). The tumor cells in these samples all contained
at least two X chromosomes (see Figure 6 and data not an HCC1937 clone (HCC Clone5) that had been stably
staining is shown in blue) are shown for IMR-90 (top) and HCC1937 (bottom). Merged image of XIST and MH2A1 staining in IMR-90 is shown
in the top right image. At least 200 cells of IMR-90 and HCC1937 were scored for MH2A1 staining, with 48% of IMR-90 and 1% of HCC
cells showing a discrete nuclear focus of MH2A1.
(D–S) Human and mouse breast and/or ovarian tumor cells were subjected to IF staining for BRCA1 and MH2A1 and to FISH for XIST RNA.
BRCA1 staining is shown for a frozen section of a sporadic ovarian cancer (D, with DAPI staining of the same section is shown in E). An
adjacent frozen section was subjected to FISH for XIST RNA (F) and another to IF for MH2A1 (G; white arrows indicate typical MH2A1 focal
staining structures). The one BRCA1/ ovarian tumor in the collection revealed no appreciable staining for BRCA1 (H, the DAPI image is in
I) and no detectable focal XIST (J) or MH2A1 staining (K). Compared to that shown in (F), the red fluorescence channel gain in (J) was increased
in an effort to detect low-level XIST staining. Spontaneous, 1687ARN mouse mammary tumor cells reveal focal nuclear staining for BRCA1
(L, with DAPI staining of these cells in M), focal Xist (N), and focal MH2A1 staining (O). W525 mouse mammary tumor cells that lack wt BRCA1
showed no detectable BRCA1 staining (P, with DAPI staining of these cells in Q), no focal Xist (R), and no focal MH2A1 staining (S). All the
XIST staining is depicted in red with DAPI counterstaining of these nuclei in blue.
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Figure 3. XIST RNA FISH Analysis of Naive and BRCA1-Reconstituted HCC1937 Cells
(A and B) XIST RNA FISH staining of vector-reconstituted HCC (A) or HCC that were stably reconstituted with wt BRCA1 (B).
(C–E) HCC stably transfected with a doxycycline-inducible wt BRCA1 vector (HCC Clone 5) were exposed to doxycycline for 24 hr. The cells
were then paraformaldehyde fixed and subjected to combined immunostaining for BRCA1 (D) and RNA FISH for XIST (E). Nuclei were stained
with DAPI (C). The arrow points to the region of greatest BRCA1 staining intensity, which coincides with the region that stains for XIST RNA.
(F–H) HCC Clone 5 were exposed to doxycycline to induce expression of BRCA1. DNA FISH for an X chromosome probe (F) and RNA FISH
for XIST (G) were performed on the same cells. A merged image is shown in (H).
(I–K) RNA FISH for XIST (red) was performed in HCC stably reconstituted with either wt BRCA1 (K), or with vectors encoding clinically relevant
BRCA1 mutant proteins bearing a missense mutations either in the RING domain, C61G (I), or in a BRCT domain, P1749R (J). DAPI staining
of the nuclei is shown in blue.
(L) Total RNA was extracted from mock-reconstituted HCC1937 cells, from HCC cells reconstituted with wt BRCA1, and from naive IMR-90
and subjected to RT-PCR with primers specific for XIST RNA. The products were separated in 2% agarose gels and visualized by ethidium
bromide staining.
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Figure 4. Effect of BRCA1 RNAi on XIST/Xi
Staining
WI-38 were transfected with control siRNA
(top) or with BRCA1-specific siRNA (bottom).
After 72 hr, all cells were analyzed by immu-
nostaining for BRCA1 (left) and by FISH for
XIST RNA (right).
transfected with a doxycycline-inducible BRCA1 allele. transcription or degradation in at least some cell types
cannot be ruled out.Upon exposure to doxycycline,10% of the cells exhib-
ited bright BRCA1 nuclear staining. Nearly all of these
induced cells (95%) also displayed focal nuclear accu- Effect of Suppressing BRCA1 Synthesis
mulation of XIST RNA (Figures 3C–3E). Although immu- on XIST/Xi Costaining
nostaining of the overexpressed BRCA1 was more dif- Small interfering RNA-mediated depletion (RNAi) spe-
fuse than is normally the case for endogenous BRCA1 cific for BRCA1 was employed to inhibit BRCA1 synthe-
in other cell lines, the most intense staining typically sis in cultured cells (Elbashir et al., 2001). Transfection of
concentrated over the XIST-bearing foci, suggesting the diploid female strain, WI-38, with a BRCA1-specific
that BRCA1 and XIST had colocalized therein (Figures RNAi, but not a control RNA, led to marked suppression
3D and 3E). Simultaneous X chromosomal DNA FISH of BRCA1 synthesis after 72 hr (Figure 4) and a marked
and RNA FISH for XIST revealed that the XIST staining decrease in focal XIST staining (Figure 4; 91%  2% of
focus in these induced cells colocalized with one of the control cells revealed focal XIST staining versus 29% 
X chromosomes (Figures 3F–3H). Synthesis of either of 10% of the BRCA1 RNAi-treated cells). Similar results
two disease-associated BRCA1 mutant proteins failed were obtained in IMR-90 and in Ishikawa cells (endome-
to elicit focal XIST staining (Figures 3I–3K). Thus, intact trial cancer cells; data not shown). Thus, acute suppres-
BRCA1 appears to be required for focal XIST staining sion of BRCA1 synthesis was associated with a signifi-
in this setting. cant loss of focal XIST staining.
Similarly, BRCA1 RNAi of asynchronous IMR-90 cells
was associated with marked suppression of focalXIST RNA Levels in HCC1937 Cells
MH2A1 staining of Xi. No such effect was observed inXIST RNA levels in vector- and wt BRCA1-reconstituted
control RNAi-treated cells analyzed in parallel (46% ofHCC1937 cells were compared by RT-PCR. Standard
control cells had focal MH2A1 staining, compared withRT-PCR analyses revealed equivalent XIST RNA levels
14% of BRCA1 RNAi-treated cells). Of note, RNAi-medi-in these cells (Figure 3L). These results were confirmed
ated suppression of BRCA2 synthesis did not lead to aby quantitative, real-time RT-PCR (Figure 3M). Similarly,
change in focal XIST staining in IMR-90 (S.G., D.P.S.,there was no difference in XIST RNA levels in uninduced
and D.M.L., unpublished results).versus doxycycline-induced HCC Clone5 (data not
shown). Therefore, introduction of wt BRCA1, although
sufficient to induce widespread focal XIST staining in BRCA1-Deficient Tumor Cells Lack Focal Histone
H3 Methylation on Lysine 9HCC1937, did not affect the XIST RNA level. Hence, in
HCC1937 cells, BRCA1 does not affect either XIST RNA The pattern of histone H3 methylation on lysine 9
(H3mK9) of the X chromosomes of BRCA1/ versussynthesis or stability. Instead, it appears to support XIST
localization on Xi. In the absence of data from other cell BRCA1/ cells was also assessed. H3/lys9 methylation
occurs in certain transcriptionally silenced, heterochro-lines/strains, a role for BRCA1 in the regulation of XIST
(M) Total RNA from vector- and BRCA1-reconstituted HCC1937 was subjected to quantitative RT-PCR using primers specific for XIST or for
TATA binding protein (TBP), an internal control. Fluorescence intensity is plotted versus cycle number. Each data point represents the mean
and standard deviation of three measurements.
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Figure 5. Histone H3 (Methyl) Lysine 9 Immunostaining and X Chromosome Replication Timing in a BRCA1-Deficient Cell Line
(A) IF for Histone H3 methylated at lysine 9 (H3mK9) is shown for IMR-90 (top) and HCC1937 (bottom). Most IMR-90 cells showed a discrete
nuclear focus of H3mK9 staining, highlighted by the white arrows in two cells in the upper image. When more than 200 cells of each line were
scored for H3mK9 focal staining, 53% of IMR-90 and 1% of HCC1937 were positive.
(B) IMR-90 underwent simultaneous immunostaining for H3mK9 (left, green) and RNA FISH for XIST (middle, red with DAPI nuclear staining
in blue). Merged image (right; the overlapping signals are in yellow) demonstrates colocalization of the focal H3mK9 staining with the XIST
staining, indicating that the area of focal H3mK9 staining is the Xi.
(C) Simultaneous immunostaining for H3mK9 (left, red) and X chromosomal DNA FISH (middle, grayish green with nuclear DAPI staining shown
in blue) was performed on IMR-90 cells (top) and HCC1937 cells (bottom). A merged image of IMR-90 signals is shown in the upper right
image. A singletdoublet pattern of X chromosomal DNA FISH signals was observed for the IMR-90 cell that is depicted. The doublet signal
seen in the upper part of the cell reflects replication of this X chromosome. The other X chromosome signal, highlighted by the white arrow,
is a singlet, indicating that it has not yet replicated. This late-replicating X chromosome colocalized with the focus of H3mK9 staining in this
cell. No unifocal H3mK9 staining was detected in the HCC1937 cell.
(D) HCC1937 cells and WI-38 female diploid fibroblasts were briefly labeled with BrdU and processed for both DNA FISH using an X chromosome-
specific probe and for immunostaining for BrdU. The pattern of FISH staining seen in BrdU-positive cells was scored for at least 50 cells of
each cell type. Cells with “two singlets” are cells in which neither X has yet replicated. Cells with a “singletdoublet” pattern contain one
unreplicated and one replicated X. In cells that contain “two doublets,” both Xs have replicated.
matic regions (Lachner and Jenuwein, 2002). Moreover, observations point to a significant alteration in the chro-
matin structure of what would otherwise have been thein female cells there is a large concentration of H3mK9
on Xi (Figures 5A–5C; Heard et al., 2001; Peters et al., Xi in these cells.
H3mK9 immunofluorescent staining was also per-2002). Although HCC1937 cells contain least two X chro-
mosomes, they lack any focal H3mK9 staining (Figures formed on frozen sections of sporadic and BRCA1-defi-
cient human breast cancers. As seen in Figure 6 and5A–5C). Replication timing analysis of the X chromo-
somes by FISH also showed that, unlike normal diploid Table 2, tumor cells arising in a women with a germline
mutation in BRCA1 lack focal H3mK9 staining, whilefibroblasts, HCC1937 fail to demonstrate asynchronous
replication of their X chromosomes (Figure 5D). These bordering normal cells had intact staining. By contrast,
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401
Figure 6. H3mK9 Immunostaining in Human Breast Cancer Tissue
(A) Hematoxylin and eosin (H & E)-stained, frozen section of a breast cancer arising in a woman with a germline BRCA1 mutation. The section
contains a focus of tumor cells bounded by a ring of normal epithelial (and other) cells.
(B) The region highlighted with the white box in (A) was examined in higher power on an adjacent frozen section that was processed for IF
using H3mK9 Ab. The normal cells at the periphery of this structure show clear unifocal nuclear staining (one focus is highlighted with a white
arrow). However, the tumor cells within this cell boundary revealed no discrete staining (5% of cells in malignant regions revealed focal
nuclear staining when 200 cells from multiple regions of the tumor were analyzed). Similar results were obtained when frozen sections of
two other breast cancers arising in women with germline BRCA1 mutations were stained for H3mK9 (see Table 2).
(C) DNA FISH using an X chromosome-specific probe was performed on an adjacent section of the same tumor shown in (A) and (B) with the
FISH signal shown in green and DAPI nuclear staining in blue. Four representative tumor cells are shown, each revealing two X chromosomes.
(D) H & E staining of a sporadic breast cancer (this tumor revealed typical nuclear BRCA1 immunostaining, data not shown).
(E) High-power view of H3mK9 IF performed on an adjacent tumor section, demonstrating the staining of a focal nuclear structure in many
of these cells (some examples are highlighted by a white arrow). When 200 cells were examined, 56% of cells in malignant regions of the
frozen section revealed discrete nuclear H3mK9 foci.
(F) X chromosome-specific DNA FISH is shown for representative cells from this tumor.
focal H3mK9 staining was detected in tumor cells from inactivated, and thus the GFP transgene is silenced.
These cells were either mock-transfected, transfectedsporadic, BRCA1-expressing breast cancers. Most cells
of these tumors contain two X chromosomes (Figure 6). with a control siRNA, transfected with a BRCA1-specific
siRNA, or exposed to 5-azacytadine (AZC). AZC served
as a positive control, leading to reactivated expressionState of X Chromosome Gene Expression
in BRCA1-Depleted Cells of the GFP allele in a fraction of cells of this and related
cell lines (Csankovszki et al., 2001). These cultures wereTo determine whether acute suppression of BRCA1 syn-
thesis leads to a detectable change in Xi gene expres- analyzed for GFP expression by FACS. As expected, by
comparison with controls, treatment with AZC led tosion, we analyzed a female murine fibroblast cell line in
which one X chromosome carries a nonfunctioning XIST the appearance of GFP-positive cells (Figure 5B). The
culture transfected with the BRCA1 RNAi also repeat-allele and the other X expresses a wt XIST allele and
carries a GFP transgene (similar to cells analyzed by edly displayed GFP-expressing cells (Figure 5B). The
relative increase in GFP-expressing cells over back-Csankovszki et al. [2001]). The latter X chromosome is
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Figure 7. Effect of BRCA1 RNAi on Expression of an Xi GFP Transgene
A murine fibroblast line that carries a nonfunctional Xist allele on one X chromosome and a GFP transgene on the other was either mock-
transfected, transfected with control RNAi, transfected with BRCA1-specific RNAi, or exposed to 5-azacytadine (AZC). After 72 hr, cells were
analyzed by FACS for GFP expression. The number of cells gated GFP positive/100,000 cells is plotted for each condition. The mean and SE
of at least three separate experiments are shown for each point. The inset figures depict the effect of BRCA1-specific RNAi on BRCA1
immunofluorescence in these cells. The figures on the right show a set of FACS profiles from one such experiment. The data are plotted as
GFP fluorescence (y axis) versus forward scattering (x axis) of cells treated with control RNAi, BRCAi RNAi, or with AZC. For purposes of
clarity, only data for cells that were gated positive (as determined by GFP fluorescence intensity and highlighted by the red box) are shown.
The FACS profiles of the GFP-negative cells, which made up the vast majority of the cells in all conditions, were similar in all cases.
ground, both after AZC or BRCA1 RNAi treatment, al- BRCA1 RNAi performed in human cells also led to
specific suppression of macroH2A1 immunostaining ofthough clearly incomplete, was similar in magnitude to
Xi. Therefore, acute loss of BRCA1 expression resultedthe effect observed when the XIST gene was deleted
in a significant change in both XIST localization on Xifrom an analogous somatic murine cell line (Csankovszki
and the associated histone composition of Xi. Takenet al., 2001).
together, these findings suggest that BRCA1 contrib-
utes to the continued association of Xi with certain key
Discussion partner molecules that, in early embryonic cells, appear
to contribute to the genesis of Xi. Whether BRCA1 partic-
BRCA1 localizes, in part, on the inactive X chromosome ipates in the initiation of X inactivation in the embryo is
both in pachytene spermatocytes and in female somatic as yet unknown. These findings are also consistent with
cells. Moreover, it and its heterodimeric partner, BARD1, (although they do not prove) the hypothesis that BRCA1
directly or indirectly interact with XIST RNA. Notably, dysfunction increases the risk of failure of the mainte-
BARD1 interacts with at least one protein engaged in nance of X chromosome inactivation.
RNA polyadenylation (Kleiman and Manley, 1999). This hypothesis is supported by the finding that acute
Whether BARD1 and/or its associated protein(s) facili- suppression of BRCA1 synthesis led to reproducible
tates the BRCA1/XIST RNA interaction remains to be albeit inefficient expression of a formerly silenced GFP
seen. allele located on Xi. This result is consistent, both quali-
In both diploid female fibroblasts and established cell tatively and quantitatively, with results obtained by oth-
lines, a functional link between the synthesis of wt ers (Csankovszki et al., 1999) who eliminated Xist RNA
BRCA1 and the decoration of the inactive X with XIST expression in a similar cell type and observed Xi gene
RNA was apparent. Since, unlike the wt protein, two activation in a small fraction of the culture. Whether the
clinically relevant BRCA1 missense mutants failed to effect of BRCA1 loss on Xi silencing is completely due
induce XIST staining in BRCA1/ cells, it appears that to the effect of BRCA1 loss on XIST localization is un-
intact BRCA1 function is needed for XIST staining of Xi. clear. In principle, loss of BRCA1 may have other conse-
No measurable difference in XIST RNA levels was quences, for example, compromise of genomic integrity
observed between vector- and BRCA1-reconstituted control, that independently affect Xi structure and si-
HCC cells, although focal XIST staining on an X chromo- lencing.
some appeared in 65% of the latter. Thus, BRCA1 HCC1937 cells lack focal staining of an X chromosome
likely contributes to XIST/Xi localization, and one might with XIST, MH2A1, and H3mK9, and both X chromo-
hypothesize that its biochemical association with XIST somes in these cells replicated synchronously. Thus,
contributes to this process. However, a role for BRCA1 neither X in this established BRCA1/ tumor cell line
in the regulation of transcription or degradation of XIST bears any of four established characteristics of Xi. Simi-
larly, each member of a set of human BRCA1-deficientRNA in other cell types cannot be ruled out.
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breast carcinomas revealed no XIST, MH2A, and histone structure in Drosophila (Kelley and Kuroda, 2000). There
H3(me)lys9 staining of either X chromosome. By con- is also a role for RNA molecules in supporting the higher-
trast, two sporadic, BRCA1-expressing carcinomas (one order structure of pericentromeric heterochromatin
ovarian and one breast) revealed clear XIST and MH2A1 (Maison et al., 2002). Thus, RNA plays a greater role in
staining. In addition, the aforementioned breast cancer chromatin structure control than previously considered.
and one other sporadic, BRCA1-expressing breast car- Conceivably, the interaction of BRCA1 with XIST RNA
cinoma also revealed focal H3mK9 staining. These find- is a reflection of a larger role for BRCA1 in influencing
ings suggest a link between chronic BRCA1 loss and other aspects of chromatin structure control through
defects in multiple aspects of Xi chromatin structure. specific RNA interactions.
If the absence of focal H3mK9 staining in BRCA1/ Finally, there are families carrying germline loss of
tumor cells mirrors a major defect in Xi silencing, how function BRCA1 mutations in which X inactivation is not
might such a result fit with the relatively inefficient reacti- random in affected family members (Buller et al., 1999).
vation of an Xi gene observed after BRCA1 RNAi (see Further work will be required to learn whether these
Figure 7)? One possibility is that complete and chronic observations are related to the suggested participation
absence of BRCA1 has a more powerful effect on Xi gene of BRCA1 in the maintenance of Xi heterochromatin
expression than its transient and incomplete depletion. structure.
Another is that additional genetic/epigenetic alterations
beyond full BRCA1 loss might be needed to disrupt Xi Experimental Procedures
silencing. In this regard, most BRCA1-deficient tumor
Cellscells are aneuploid, genomically unstable, contain multi-
HCC1937 cells and their BRCA1-reconstituted derivatives haveple regions of LOH, bear p53 loss of function mutations,
been described previously (Scully et al., 1999). Ishikawa and telo-
and likely harbor additional gene defects (Venkitaraman, merase-imortalized HMEC-t were a kind gift of Myles Brown.
2002). 1687ARN was a generous gift of Jing Yang and Robert Weinberg.
Multiple BRCA1/ primary tumors exhibited defects
in Xi chromatin structure, raising the question of whether Antibodies
Monoclonal antibodies to mouse (GH118) and human BRCA1these defects contribute to BRCA1-associated breast
(SD118, MS110, SG11) were used at a 1:10 dilution of hybridomaand ovarian tumorigenesis. This hypothesis is posed
supernatant for immunofluorescence analyses. Affinity-purifiedwith the knowledge that X heterochromatinization and
polyclonal BRCA1 and BARD1 antibodies were described previouslyBRCA1 tumorigenesis are both female-specific events.
(Cantor et al., 2001; Chen et al., 1998). In immunofluorescence analy-
Moreover, prior evidence supports a role for abnormal ses, affinity-purified macroH2A1 antibody was used at a 1:500 dilu-
X chromosome behavior in breast and ovarian cancer. tion, anti-histone H3(me)lys9 antibody at a 1:500 dilution, and anti-
Notably, a subset of aggressive breast and ovarian car- BrdU (Becton Dickinson) at a 1:7 dilution.
cinomas were shown to lack a detectable Barr body
Immunostaining(Kimmel, 1957; Moore and Barr, 1957; Perry, 1972; Sa-
Immunostaining was performed on paraformaldehyde (PFA)-fixedvino and Koss, 1971). Furthermore, compared to spo-
cultured cells, as previously described (Scully et al., 1997). All sam-radic ovarian cancers, BRCA1-deficient ovarian cancers
ples were mounted with Vectashield containing DAPI (Vector Labs)
manifest overexpression of a set of X chromosomal prior to viewing.
genes (Jazaeri et al., 2002). However, it should be em- Mouse testis sections from 2-month-old males mice were rapidly
phasized that, at present, there is no evidence to support fixed in PBS and 3% PFA/PBS. They were then postfixed for 1 hr
in 3% PFA/PBS and cryoprotected by O/N incubation in 20% su-a causal link between the effect of BRCA1 loss on Xi
crose at 4C. 5–10 m cryotome sections were then processed forand tumor development.
immunostaining as described above.The effect on Xi chromatin structure might be a reflec-
tion of a more general function of BRCA1. Perhaps the
RNA Fluorescence In Situ Hybridization (FISH)ability of BRCA1 to interact with XIST and to influence
Adherent, cultured cells or frozen sections of tumor samples were
XIST/Xi localization is biochemically related to the exe- fixed in 3% PFA and then processed for RNA FISH as described
cution of BRCA1 genomic integrity maintenance func- (Clemson et al., 1996; Lee and Jaenisch, 1997). For combined immu-
tion. BRCA1 is not exclusively localized on the inactive nostaining and RNA-FISH, samples were processed as described
above for immunostaining, with RNAGuard (Amersham) added toX chromosome, even in female cells. Rather, during S
all antibody incubations at a final concentration of 40 U/ml. Afterphase, it also concentrates in another group of focal,
final washes, samples were refixed by incubation with 3% PFA/PBSnuclear structures (nuclear dots; Scully et al., 1997).
for 20 min at 25 C. The samples were then processed for RNA-FISHSince the inactive X chromosome is a prominent form
as described above.
of facultative heterochromatin, it is possible that the
nuclear dots are also heterochromatic elements. If so, Interphase DNA FISH
perhaps BRCA1 participates in regulating the structure Cells were fixed with paraformaldehyde, as described above. DNA
and function of certain heterochromatic structures after FISH, using labeled X chromosome probe (XCEP, Vysis) or a FITC-
labeled X chromosome paint (X-WCP, Vysis), was performed accordingthey have sustained DNA damage, thereby facilitating
to the manufacturer’s instructions. For combined RNADNA FISH,DNA repair.
samples were first processed for RNA-FISH as described above.Results presented here show that a RING domain pro-
After the final wash, the samples were crosslinked by incubationtein (BRCA1) and a noncoding RNA dedicated to dosage
with 3% paraformaldehyde/PBS for 20 min at 24C. Samples were
compensation (XIST) communicate functionally in mam- then dehydrated with ethanol and processed for DNA FISH.
malian cells. Similar interactions between specific non-
coding RNA molecules and a RING domain-containing Replication Timing Analysis
protein participate in regulating sex chromosome dos- Replication timing analysis for the X chromosome was performed
as described (Squire et al., 2000).age compensation through the control of chromatin
Cell
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Analysis of Frozen Tumor Sections and Jeanne Bentley Lawrence for human XIST reagents. We are
indebted to Drs. Suzette Delaloge, Jean-Christian Sabourin, andFor immunostaining of tumor specimens, frozen sections were im-
mediately fixed by incubation with 3% PFA/PBS for 15 min at room Andrea Richardson for providing clinical tumor samples for analysis.
This work was supported by grants from the National Cancer Insti-temperature. The fixed sections were processed for immunostaining
and RNA FISH as described above. Adjacent sections were stained tute, including a Dana-Farber/Harvard SPORE in breast cancer, by
a Physician-Scientist Post Doctoral Fellowship from the Howardwith hematoxylin and eosin and viewed to identify regions having
abundant malignant cells. 200 malignant cells from each section Hughes Medical Institute (to S.G.), and by the Women’s Cancer
Program of the Dana-Farber Cancer Institute. J.F. is supported bywere assessed for the presence of focal XIST or MH2A1 staining.
Tumors were scored () for XIST, MH2A1, or H3mK9 focal nuclear a grant from ARC.
staining if 5% of the tumor cells analyzed were positive.
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